Dharam Mann, MD
Interventional Pain Management · Whiting, NJNPI 1063463099
Payments from drug & device makers
Across 185 payments — averaging $10,613 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SPR Therapeutics, Inc$1.9M
- Foundation Fusion Solutions, LLC$10K
- Abbott$2K
- Vertiflex, Inc.$1K
- Medtronic$1K
- Boston Scientific$297
- plus $1K from 10 others
What the payments were for
- Food & beverage$5,02333%
- Ownership interest$10,09067%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SPR Therapeutics, Inc | 7 | $1,947,116 |
| Foundation Fusion Solutions, LLC | 1 | $10,090 |
| Abbott | 115 | $1,962 |
| Vertiflex, Inc. | 11 | $1,388 |
| Medtronic(2 entities) | 26 | $1,311 |
| Boston Scientific | 8 | $297 |
| Stimwave Technologies Incorporated | 2 | $220 |
| Axonics, Inc. | 2 | $196 |
| Olympus America Inc. | 2 | $177 |
| Vertos Medical, Inc. | 4 | $140 |
| Relievant Medsystems, Inc. | 2 | $120 |
| Painteq LLC | 1 | $116 |
| Procept Biorobotics Corporation | 1 | $99 |
| Globus Medical | 1 | $69 |
| Spinefrontier, Inc. | 1 | $63 |
| Linus Health, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$219
- Intracept$202
- RESTORE$158
- ETERNA$154
- INTERSTIM$150
- iTIND System$147
- SUPERION$145
- Axonics r-SNM System$129
- OCTRODE$123
- Proclaim IPG$123
- Vanta$121
- PAINTEQ$116
- Superion ISS$115
- mild Device Kit$102
How this compares
Too few interventional pain management providers in New Jerseyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 26 | $12,231 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 431 | $9,856 |
| Lidocaine | 28 | $4,655 |
| Gabapentin | 298 | $4,043 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 144 | $3,536 |
| Pregabalin | 73 | $2,428 |
| Oxycodone Hcl | 124 | $1,976 |
| Morphine Sulfate ErMorphine Sulfate | 37 | $1,471 |
| Tramadol Hcl | 256 | $1,451 |
| Diclofenac Sodium | 26 | $1,418 |
| Clonidine | 13 | $1,359 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 11 | $1,160 |
| Morphine Sulfate | 38 | $1,068 |
| Tizanidine Hcl | 44 | $649 |
| Cyclobenzaprine Hcl | 38 | $623 |
Paid to pharmacies, not to this prescriber.
Other interventional pain management in Whiting
- Sanjiv ParikhRutherford$5K
- Anil SharmaShrewsbury$1K
- Moises KaweblumLakewood$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.